Sensus Healthcare's Q4 2024: Navigating Contradictions in Fair Deal Strategy and International Expansion

These are the key contradictions discussed in Sensus Healthcare's latest 2024Q4 earnings call, specifically including: Fair Deal Agreement strategy, Expansion into the International Market, Fair Deal Agreement placements and impact on revenues, and Customer Acquisition Strategy:



Revenue Growth and Market Acceptance:
- Sensus Healthcare reported record revenue of $13.1 million for Q4 2024, up 71% compared to 2023, and $41.8 million for the year.
- The growth was driven by higher unit sales of SRT-100 systems due to expanding clinical awareness and broader reimbursement for superficial radiation therapy.

Fair Deal Agreement Program:
- The Fair Deal Agreement Program has shown significant traction, with interest among corporate accounts surpassing expectations.
- These agreements, accommodating a wide range of potential customers with a structured, tiered revenue sharing component, are expected to contribute meaningfully to the top line in the second half of 2025.

International Expansion:
- Sensus Healthcare shipped 10 systems internationally in 2024, advancing its approach to deepen relationships with established distributors across multiple geographies.
- This expansion is aimed at addressing the significant unmet need for non-invasive treatment options in various international markets.

FDA Approval and Product Innovation:
- Sensus Healthcare is preparing to resubmit its TBI-510K application in the first half of 2025, with enhancements made in response to SBA feedback.
- This resubmission is part of the company's strategy to diversify its product line and solidify its footprint in the dermatology market.